AVADEL PHARMACEUTICALS PLCAVDLEarnings & Financial Report
Nasdaq
Avadel Pharmaceuticals, is an Irish specialty pharmaceutical company that focuses on sleep disorder medicines. Avadel markets products in the hospital and primary care spaces. The company is headquartered in Dublin, Ireland with operations in St. Louis, Missouri and Lyon, France.
NextMar 31, 2026
AVDL Q3 2025 Key Financial Metrics
Revenue
$77.5M
Gross Profit
$81.6M
Operating Profit
$1.9M
Net Profit
$20.0K
Gross Margin
105.3%
Operating Margin
2.5%
Net Margin
0.0%
YoY Growth
54.9%
EPS
$0.00
Financial Flow
AVADEL PHARMACEUTICALS PLC Q3 2025 Financial Summary
AVADEL PHARMACEUTICALS PLC reported revenue of $77.5M for Q3 2025, with a net profit of $20.0K (0.0% margin). Cost of goods sold was $-4.1M, operating expenses totaled $79.6M.
Key Financial Metrics
| Total Revenue | $77.5M |
|---|---|
| Net Profit | $20.0K |
| Gross Margin | 105.3% |
| Operating Margin | 2.5% |
| Report Period | Q3 2025 |
AVADEL PHARMACEUTICALS PLC Annual Revenue by Year
AVADEL PHARMACEUTICALS PLC annual revenue history includes year-by-year totals (for example, 2024 revenue was $169.1M).
| Year | Annual Revenue |
|---|---|
| 2024 | $169.1M |
| 2023 | $28.0M |
| 2022 | $0 |
Income Statement
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $19.5M | $27.2M | $41.5M | $50.0M | $50.4M | $52.5M | $68.1M | $77.5M |
| YoY Growth | N/A | N/A | 2674.3% | 613.2% | 159.1% | 93.2% | 64.2% | 54.9% |
Balance Sheet
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $164.7M | $167.9M | $157.5M | $158.3M | $164.2M | $167.9M | $187.2M | $199.4M |
| Liabilities | $77.0M | $89.5M | $87.2M | $83.6M | $90.4M | $93.9M | $96.4M | $101.2M |
| Equity | $87.7M | $78.4M | $70.3M | $74.7M | $73.8M | $74.1M | $90.7M | $98.2M |
Cash Flow
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-28.0M | $-29.7M | $-18.2M | $-6.9M | $7.9M | $-8.2M | $12.7M | $22.2M |